NU SKIN ENTERPRISES, INC. (NUS) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 1.00%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 1.00% | Share-based compensation / revenue. Period ending 2026-06-30. $13.79M ÷ $1.38B × 100 ≈ 1.00% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 1.38B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 13.79M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -10.41M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $1.38B | $13.79M | $-10.41M | (m) | (m) | 1.00% | (m) | (m) |
| 2026-03-31 | (m) | $1.44B | $18.49M | $79.69M | (m) | (m) | 1.28% | (m) | (m) |
| 2025-12-31 | $10.80M | $1.49B | $24.11M | $65.76M | (m) | 0.73% | 1.62% | (m) | (m) |
| 2025-09-30 | (m) | $1.56B | $24.39M | $-10.56M | (m) | (m) | 1.56% | (m) | (m) |
| 2025-06-30 | (m) | $1.63B | $22.06M | $-13.97M | (m) | (m) | 1.36% | (m) | (m) |
| 2025-03-31 | (m) | $1.68B | $19.89M | $-170.31M | (m) | (m) | 1.18% | (m) | (m) |
| 2024-12-31 | $13.00M | $1.73B | $14.82M | $-151.59M | (m) | 0.75% | 0.86% | (m) | (m) |
| 2024-09-30 | (m) | $1.78B | $14.50M | $-82.44M | $27.95M | (m) | 0.82% | -2.95× | Reported |
| 2024-06-30 | (m) | $1.84B | $14.73M | $-127.04M | $28.99M | (m) | 0.80% | -4.38× | Reported |
| 2024-03-31 | (m) | $1.90B | $15.89M | $41.03M | $28.04M | (m) | 0.83% | 1.46× | Reported |
| 2023-12-31 | $22.60M | $1.97B | $15.65M | $48.27M | $25.60M | 1.15% | 0.79% | 1.89× | Reported |
| 2023-09-30 | (m) | $2.00B | $15.57M | $59.66M | (m) | (m) | 0.78% | (m) | (m) |
| 2023-06-30 | (m) | $2.04B | $15.02M | $65.75M | (m) | (m) | 0.74% | (m) | (m) |
| 2023-03-31 | (m) | $2.10B | $12.24M | $74.77M | (m) | (m) | 0.58% | (m) | (m) |
| 2022-12-31 | $23.30M | $2.23B | $12.37M | $110.85M | $13.50M | 1.05% | 0.56% | 8.21× | Reported |
| 2022-09-30 | (m) | $2.38B | $16.04M | $103.71M | (m) | (m) | 0.67% | (m) | (m) |
| 2022-06-30 | (m) | $2.48B | $15.96M | $189.38M | (m) | (m) | 0.64% | (m) | (m) |
| 2022-03-31 | (m) | $2.62B | $20.52M | $223.22M | (m) | (m) | 0.78% | (m) | (m) |
| 2021-12-31 | $27.20M | $2.70B | $23.19M | $233.99M | $11.00M | 1.01% | 0.86% | 21.27× | Reported |
| 2021-09-30 | (m) | $2.77B | $25.10M | $302.37M | (m) | (m) | 0.91% | (m) | (m) |
| 2021-06-30 | (m) | $2.83B | $29.12M | $311.21M | (m) | (m) | 1.03% | (m) | (m) |
| 2021-03-31 | (m) | $2.74B | $27.41M | $283.91M | (m) | (m) | 1.00% | (m) | (m) |
| 2020-12-31 | $23.30M | $2.58B | $24.06M | $257.56M | $13.10M | 0.90% | 0.93% | 19.66× | Reported |
| 2020-09-30 | (m) | $2.42B | $15.70M | $223.55M | (m) | (m) | 0.65% | (m) | (m) |
| 2020-06-30 | (m) | $2.30B | $9.60M | $219.21M | (m) | (m) | 0.42% | (m) | (m) |
| 2020-03-31 | (m) | $2.31B | $8.32M | $235.34M | (m) | (m) | 0.36% | (m) | (m) |
| 2019-12-31 | $30.10M | $2.42B | $9.91M | $267.43M | $19.20M | 1.24% | 0.41% | 13.93× | Reported |
| 2019-09-30 | (m) | $2.52B | $15.95M | $231.18M | (m) | (m) | 0.63% | (m) | (m) |
| 2019-06-30 | (m) | $2.61B | $21.98M | $241.96M | (m) | (m) | 0.84% | (m) | (m) |
| 2019-03-31 | (m) | $2.69B | $24.89M | $250.52M | (m) | (m) | 0.93% | (m) | (m) |
| 2018-12-31 | $23.00M | $2.68B | $26.61M | $240.86M | $21.80M | 0.86% | 0.99% | 11.05× | Reported |
| 2018-09-30 | (m) | $2.66B | $25.13M | $321.55M | (m) | (m) | 0.94% | (m) | (m) |
| 2018-06-30 | (m) | $2.55B | $25.00M | $305.24M | (m) | (m) | 0.98% | (m) | (m) |
| 2018-03-31 | (m) | $2.40B | $22.15M | $287.21M | (m) | (m) | 0.92% | (m) | (m) |
| 2017-12-31 | $22.00M | $2.28B | $19.31M | $274.48M | $22.20M | 0.97% | 0.85% | 12.36× | Reported |
| 2017-09-30 | (m) | $2.14B | $18.22M | $236.15M | (m) | (m) | 0.85% | (m) | (m) |
| 2017-06-30 | (m) | $2.18B | $8.88M | $254.16M | (m) | (m) | 0.41% | (m) | (m) |
| 2017-03-31 | (m) | $2.24B | $10.37M | $269.22M | (m) | (m) | 0.46% | (m) | (m) |
| 2016-12-31 | $24.30M | $2.21B | $8.89M | $231.10M | $15.60M | 1.10% | 0.40% | 14.81× | Reported |
| 2016-09-30 | (m) | (m) | $8.12M | $232.03M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | $7.56M | $192.20M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | $6.29M | $184.21M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $20.10M | (m) | $7.40M | $244.70M | $7.90M | (m) | (m) | 30.97× | Reported |
| 2015-09-30 | (m) | (m) | $5.63M | $274.29M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | $11.20M | $336.70M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | $12.38M | $319.64M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $18.90M | (m) | $17.50M | $352.19M | $5.70M | (m) | (m) | 61.79× | Reported |
| 2014-09-30 | (m) | (m) | $25.94M | $449.49M | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | $34.94M | $512.80M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | $35.59M | $572.65M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $18.00M | $3.18B | $32.62M | $554.11M | $3.00M | 0.57% | 1.03% | 184.70× | Reported |
| 2013-09-30 | (m) | (m) | $28.11M | $454.42M | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | $21.64M | $368.51M | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | $22.79M | $351.84M | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $14.90M | $2.17B | $21.36M | $340.84M | $5.20M | 0.69% | 0.98% | 65.55× | Reported |
| 2012-09-30 | (m) | (m) | $20.20M | $327.52M | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | $18.82M | $312.36M | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | $16.04M | $280.50M | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $13.60M | $1.74B | $15.45M | $233.74M | $4.80M | 0.78% | 0.89% | 48.70× | Reported |
| 2011-09-30 | (m) | (m) | $14.61M | $217.06M | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | $14.20M | $202.74M | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | $12.49M | $195.85M | (m) | (m) | (m) | (m) | (m) |
| 2011-03-30 | (m) | (m) | (m) | $241.92M | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | $10.84M | $217.06M | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $9.99M | $147.71M | (m) | (m) | (m) | (m) | (m) |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $7.27M | $125.43M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cosmos Health Inc. (COSM) | Greece | $0.038B | -0.60 |
| HWH International Inc. (HWH) | United States | $0.021B | -4.08 |
| DataMeds AI, Inc. (MEDS) | United States | $0.011B | |
| HERBALIFE LTD. (HLF) | $1.281B | 8.39 | |
| CARDINAL HEALTH INC (CAH) | United States | $51.753B | 29.38 |
| Cencora, Inc. (COR) | United States | $59.130B | 20.57 |
| MCKESSON CORP (MCK) | United States | $101.317B | 19.78 |